Sirio Pharma Co., Ltd. (SHE:300791)

China · Delayed Price · Currency is CNY

17.11

-0.35 (-2.00%)

Aug 4, 2026, 3:04 PM CST

-26.25% (1Y)

Market Cap	5.25B -25.9%
Revenue (ttm)	4.31B +2.3%
Net Income	117.80M -64.4%
EPS	0.39 -64.7%
Shares Out	307.02M
PE Ratio	44.38
Forward PE	14.08
Dividend	0.13 (0.74%)
Ex-Dividend Date	Jun 5, 2026

Volume	1,760,615
Open	17.46
Previous Close	17.46
Day's Range	17.06 - 17.64
52-Week Range	15.40 - 26.45
Beta	0.31
Analysts	Buy
Price Target	25.00 (+46.11%)
Earnings Date	Aug 29, 2026

About Sirio Pharma

Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry China, the United States, Europe, and internationally. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutritious gummies; liquids; probiotic balls; tablet and powder products; capsules; and functional beverages for beauty and wellness, gut health, bone and joint health, immune and fertility support, cardiovascular and metabolic health, and healthy ageing. It also offers formulation; technical, and researc... [Read more]

Industry Packaged Foods

Sector Consumer Staples

Founded 1993

Employees 2,776

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300791

Full Company Profile

Financial Performance

In 2025, Sirio Pharma's revenue was 4.26 billion, an increase of 1.23% compared to the previous year's 4.21 billion. Earnings were 136.53 million, a decrease of -58.00%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 300791 stock is "Buy." The 12-month stock price target is ¥25.00, which is an increase of 46.11% from the latest price.

Price Target

¥25.00

(46.11% upside)

Analyst Consensus: Buy

Stock Forecasts